Silo Pharma, Inc. · NASDAQ:SILO
Silo Pharma — Investor Presentation (October 2022)
24 slides from Silo Pharma's investor presentation, Oct 18, 2022
Slide 1: Corporate Presentation Fall 2022
Corporate Presentation Nasdaq: SILO 1 Fall 2022
Slide 2: Forward-Looking Statements
Nasdaq: SILO | | | | | | | | | | | Statement This presentation contains "forward - looking statements" within the meaning of the “safe - harbor” provisions of the Private Securities Litigation Reform Act of 1995 . These statements are identified by the use of words “could”, “believe”, “anticipate”,
Slide 3: Psychedelic Research
| | | | | | | | | | | | | | | | | | | | | | | Psychedelic Research Silo Pharma is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research. Five novel drug candidates are under development for large, underserved medical markets: ◉ Alzheime
Slide 4: Considerations
| | | | | | | | | | Considerations 4 Nasdaq: SILO ◉ Established collaborations with leading academic institutions facilitate streamlined 505(b)(2) regulatory pathway for drug approval. ◉ Disruptive market potential for novel IP - protected technologies and assets. ◉ Burgeoning psychedelic drugs mark
Slide 5: Collaborations and Assets
SPU - 16 | Multiple Sclerosis ◉ Central nervous system homing peptide ◉ Only targets tissue affected by certain conditions | | | | | | | | | | Collaborations and Assets 5 Nasdaq: SILO SP - 26 | Multiple indications ◉ Time - released psilocybin, ketamine ◉ Topical drug delivery system developed at Al
Slide 6: Development Timeline
| | | | | | | | | | Development Timeline 6 Nasdaq: SILO Drug Indication Optimization/ Proof of Concept Preclinical Phase I Phase II Phase III Launch SP - 26 Fibromyalgia, Multiple SPU - 16 Peptide Multiple Sclerosis (MS) SPU - 21 Peptide Rheumatoid Arthritis (RA) SPC - 14 Alzheimer’s Disease (AD) SP
Slide 7: Intellectual Property Position
| | | | | | | | | | | | | | | | Property Position > Five patents issued and provisional US Patent issued 11 / 16 / 21 # 11174287 Central Nervous System Homing Peptides US # 8 , 623 , 377 Joint - Homing peptide U . S . Provisional Patent Application No . 63 / 060 , 573 , titled “Central Nervous Syste
Slide 8: Asset Portfolio
Asset Portfolio Nasdaq: | SILO 8
Slide 9: SP-26 Time-Released Psilocybin, Ketamine
SP - 26 Time - Released Psilocybin, Ketamine ▪ Fibromyalgia and multiple other i ndications Market Opportunity: ▪ Deliver ketamine or psilocybin in a time - released manner ▪ Determining if time - release will diminish hallucinogenic effects of these psychedelics ▪ Preclinical study underway shows Z
Slide 10: SPU-16 CNS Homing Peptide: Multiple Sclerosis
SPU - 16 CNS Homing Peptide ▪ A pproximately 400,000 Americans and 2.5 million people worldwide with MS ▪ M ost widespread disabling neurological condition of young adults ▪ Global market for MS drugs expected to reach $25.3 billion by 2027 Market Opportunity: Multiple Sclerosis (MS) ▪ May be used a
Slide 11: SPU-21 Joint Homing Peptides Targeting Rheumatoid Arthritis
SPU - 21 Joint Homing Peptides Targeting Rheumatoid Arthritis ▪ 1.3M U.S. adults suffer from RA ▪ The most common autoimmune disease in U.S. ▪ U.S. market for RA drugs expected to reach $63 billion by 2027 Market Opportunity: Rheumatoid Arthritis (RA) ▪ Identify markers of arthritic inflammation in
Slide 12: SPC-14 Targeting Alzheimer's
SPC - 14 Targeting Alzheimer's ▪ 6.5 million Americans suffer from Alzheimer’s and related diseases ▪ ~1 in 9 Americans 65+ have Alzheimer’s ▪ U.S. market for relevant drugs expected to reach $5 billion by 2027 Market Opportunity: Alzheimer’s Disease ▪ 505(b)(2) Pathway ▪ Preclinical testing and pro
Slide 13: SPC-15 Stress-Induced Affective Disorders
SPC - 15 Targeted Prophylactic Treatment — Stress - Induced Affective Disorders ▪ 26% of Americans 18+ suffer from anxiety, PTSD and other disorders ▪ This number has escalated post - COVID - 19 ▪ U.S. market for relevant drugs expected to reach $13 billion by 2027 Market Opportunity: Stress - induc
Slide 14: Clinical Study: Effect of Psilocybin on Inflammation in the Blood
Clinical Study: Effect of Psilocybin on Inflammation in the Blood ▪ Parkinson’s Disease, chronic pain, and bipolar disorder Market Opportunity: Multiple Indications ▪ Examine effects of psilocybin on inflammatory activity in humans ▪ Accelerate its implementation as a potential treatment Application
Slide 15: Leadership
Leadership Nasdaq: | SILO 15
Slide 16: Leaders
| | | | | | | | | Leaders Eric Weisblum CEO ◉ 20+ years investing, building and managing businesses ◉ Prior president of Sableridge Capital ◉ Former board member of Aikido Pharma., a Nasdaq - listed biotech company focused on the commercialization of oncology therapeutics James Kuo , M.D. Vice Presi
Slide 17: Advisory Board
| | | | | | | | | Advisory Board Charles B. Nemeroff M.D., Ph.D. ◉ Chair, Department of Psychiatry and Behavioral Sciences, Dell Medical School, University of Texas at Austin; director, Institute for Early Life Adversity Research, Department of Psychiatry and Behavioral Sciences, Mulva Clinic for th
Slide 18: Directors
| | | | | | | | Directors Wayne Linsley Director ◉ 40 years in business management ◉ Wide and varied skillset including sales and sales management, finance (for both public and private companies), accounting, audit support and financial reporting ◉ Independent director for Hoth Therapeutics Inc. (NA
Slide 19: Key Takeaways
Key Takeaways Nasdaq: | SILO 19
Slide 20: Highlights
| | | | | | | | | Highlights 20 Nasdaq: SILO ◉ 505(b)(2) regulatory pathway provides competitive time - to - market advantage over other early psychedelic drug market entrants. ◉ Diversified pipeline drugs showing promise in underserved rare disease, neurological, and mental health indications. ◉ Ma
Slide 21: Priorities
| | | | | | | | | | Priorities 21 Nasdaq: SILO Clinical study update. Advance SP - 26 topical time - released ketamine to th e clinic . Pursue initial indication of fibromyalgia for SP - 26 . Advance studies of SPU - 21 in progress at UMB. Ongoing intellectual property and patent expansion. Data fro
Slide 22: Measures of Value
| | | | | | | | | | | Measures of Value 22 Nasdaq: SILO Market capitalization* $14.0M $175.8M $531.5M $102.2M $582.2M Stage of drug development Phase 1 Phase 2 Phase 2 Phase 2 Phase 2 505(b)(2) pathway ✓ Compounds Traditional therapeutics, psilocybin, ketamine LSD, i bogaine, MDMA Psilocybin Psilocy
Slide 23: Summary
| | | | | | | | | | Summary Established collaborations with leading academic institutions Experienced drug development team Multiple large disease markets being pursued Well - capitalized balance sheet Recent uplisting to Nasdaq Strong intellectual property position 23 Nasdaq: SILO
Slide 24: Thank you
Thank you. 560 Sylvan Ave, Suite 3160 Englewood Cliffs, NJ 07632 Nasdaq: | SILO 800 - 705 - 0120 investors@silopharma.com